Progyny (PGNY) Stock: Buy, Sell, or Hold?
PGNY - Progyny, Inc. Common Stock
$27.35
0.27 (1.00%)
▲
5d:
+2.78%
30d:
+7.59%
90d:
+6.63%
BUY
HIGH Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When PGNY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: PGNY shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: PGNY shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$37.84
Based on 7.6% avg growth
INTRINSIC VALUE TODAY
$23.50
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PGNY is currently trading at $27.35, which is considered fair relative to its 30-day fair value range of $25.00 to $29.13. The stock's valuation (Forward PE: 11.8) is in line with its historical norms (11.3). At these levels, the market is pricing in 1.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PGNY is in a uptrend. The price is approaching resistance at $27.77. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PGNY scores 70/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $34.42 (+25.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PGNY is in a uptrend. The price is approaching resistance at $27.77. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PGNY scores 70/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $34.42 (+25.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$25.00 -
$29.13
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
84.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (70/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 25.8% below Wall St target ($34.42)
- NEUTRAL: Market pricing in 1.3% annual earnings growth - fairly valued
- BULLISH: Bottoming setup score 70/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$25.00 -
$29.13
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$25.46
Resistance Level
$27.77
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.79
Wall Street Target
$34.42
(+25.8%)
Revenue Growth (YoY)
5.3%
Earnings Growth (YoY)
78.9%
Profit Margin
6.0%
Valuation Premium vs History
+1.3% premium
PE vs Historical
11.8 vs 11.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.3%
(market-implied from PE analysis)
1-Year Target
$27.71
(+1%)
2-Year Target
$28.07
(+3%)
3-Year Target
$28.43
(+4%)
3-Yr Target (if PE normalizes)
(PE: 12→11)
PE COMPRESSION
$27.25
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 11.3%)
$64.47
(+136%)
Base:
(SPY PE: 11.8, Growth: 11.3%)
$37.69
(+38%)
Bear:
(PE: 10.0, Growth: 11.3%)
$32.03
(+17%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (29x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 29.43 | Current EPS (TTM): $0.92
Bull Case
$59.58
(+118%)
Analyst growth 100.0%, PE expands to 32.4
Base Case
$54.16
(+98%)
Market implied 100.0%, PE stable at 29.4
Bear Case
$18.41
(-33%)
Severe decline -20.0%, PE contracts to 25.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 14, 2026 1:41 AM ET
Data refreshes hourly during market hours. Next update: 2:41 AM
Data refreshes hourly during market hours. Next update: 2:41 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PGNY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Healthcare Plans Stocks
Top-rated stocks in Healthcare Plans by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CVS
CVS Health Corp |
STRONG BUY
28 analysts |
$116 | 50 HOLD |
|
UNH
UnitedHealth Group Incor… |
STRONG BUY
27 analysts |
$475 | 49 HOLD |
|
CI
Cigna Corp |
STRONG BUY
25 analysts |
$339 | 51 HOLD |
|
ELV
Elevance Health Inc |
STRONG BUY
22 analysts |
$450 | 45 HOLD |
|
HUM
Humana Inc |
HOLD
26 analysts |
$419 | 49 HOLD |
Advanced PGNY Option Strategies
Professional options setups generated by AI based on today's PGNY price and gamma walls.
